The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283)

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 4, 2004, Pages 313-322

  Winter, Helen R ^a   Trapnell, Carol B ^b   Slattery, John T ^a   Jacobson, Mark ^c,d   Greenspan, Debra L ^e,f   Hooton, Thomas M ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

^e MEHARRY MEDICAL COLLEGE   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; RIFABUTIN; SULFAMETHOXAZOLE; SULFAMETHOXAZOLE HYDROXYLAMINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG POTENTIATION; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL MODEL; T LYMPHOCYTE SUBPOPULATION; TABLET FORMULATION;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; CLARITHROMYCIN; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RIFABUTIN; SULFAMETHOXAZOLE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 4744341975     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.06.002     Document Type: Article

References (33)

1. A. Morris, R.M. Wachter, J. Luce, J. Turner, L. Huang Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia AIDS 17 2003 73 80
2. B.L. Lee, I. Medina, N.L. Benowitz, P. Jacob III, C.B. Wofsy, J.T. Mills Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS) Evidence of drug interactions Ann Intern Med 110 1989 606 611
3. I. Medina, J. Mills, G. Leoung, P.C. Hopewell, B. Lee, G Modin Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone N Engl J Med 323 1990 776 782
4. M.A. Martin, P.H. Cox, K. Beck, C.M. Styer, G.N. Beall A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients Arch Intern Med 152 1992 523 528
5. J.A. Kovacs, J.W. Hiemenz, A.M. Macher, D. Stover, H.W. Murray, J Shelhamer Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies Ann Intern Med 100 1984 663 671
6. A.J. van der Ven, P.P. Koopmans, T.B. Vree, J.W. van der Meer Adverse reactions to co-trimoxazole in HIV infection Lancet 338 1991 431 433
7. M. Pirmohamed, B.K. Park HIV and drug allergy Curr Opin Allergy Clin Immunol 1 2001 311 316
8. A.E. Cribb, M. Miller, A. Tesoro, S.P. Spielberg Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs Mol Pharmacol 38 1990 744 751
9. A.E. Cribb, S.P. Spielberg, G.P. Griffin N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes Drug Metab Dispos 23 1995 406 414
10. H. Nakamura, J. Uetrecht, A.E. Cribb, M.A. Miller, N. Zahid, J Hill In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity J Pharmacol Exp Ther 274 1995 1099 1104
11. M.J. Rieder, J. Uetrecht, N.H. Shear, S.P. Spielberg Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides J Pharmacol Exp Ther 244 1988 724 728
12. N.H. Shear, S.P. Spielberg In vitro evaluation of a toxic metabolite of sulfadiazine Can J Physiol Pharmacol 63 1985 1370 1372
13. J.T. Slattery, J.D. Unadkat Adverse reactions to co-trimoxazole in HIV infection [letter] Lancet 338 1991 1216
14. L. Gil, G. Martinez, I. Gonzalez, A. Tarinas, A. Alvarez, A Giuliani Contribution to characterization of oxidative stress in HIV/AIDS patients Pharmacol Res 47 2003 217 224
15. D.A. Hess, M.E. Sisson, H. Suria, J. Wijsman, R. Puvanesasingham, J Madrenas Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole FASEB J 13 1999 1688 1698
16. G.W. Pace, C.D. Leaf The role of oxidative stress in HIV disease Free Radic Biol Med 19 1995 523 528
17. M.J. Rieder, R. Krause, I.A. Bird, G.A. Dekaban Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells J Acquir Immune Defic Syndr Hum Retrovirol 8 1995 134 140
18. A. Carr, B. Tindall, R. Penny, D.A. Cooper In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV Clin Exp Immunol 94 1993 21 25
19. A. Carr, C. Swanson, R. Penny, D.A. Cooper Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS J Infect Dis 167 1993 180 185
20. E. Warren, S. George, J. You, P. Kazanjian Advances in the treatment and prophylaxis of Pneumocystis carinii pneumonia Pharmacotherapy 17 1997 900 916
21. Mitra A, Kalhorn T, Thummel K, Unadkat J, Slattery J. Metabolism of arylamines by human liver microsomal cytochrome P450(s) [abstract]. In: Proceedings of the Fifth North American Meeting of the International Society for the Study of Xenobiotics; 1993 Oct 17-21; Tucson, Arizona. Bethesda (MD): ISSX; 1993. Vol. 4; p. 148.
22. A. Mitra, K. Thummel, T. Kalhorn, E. Kharasch, J. Unadkat, J. Slattery Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers Clin Pharmacol Ther 59 1996 332 340
23. M.S. Benedetti Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs Pharmacol Res 32 1995 177 187
24. E. Iatsimirskaia, S. Tulebaev, E. Storozhuk, I. Utkin, D. Smith, N Gerber Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents Clin Pharmacol Ther 61 1997 554 562
25. A.D. Rodrigues, E.M. Roberts, D.J. Mulford, Y. Yao, D. Ouellet Oxidative metabolism of clarithromycin in the presence of human liver microsomes Major role for the cytochrome P4503A (CYP3A) subfamily Drug Metab Dispos 25 1997 623 630
26. A.E. Rettie, A.C. Eddy, L.D. Heimark, M. Gibaldi, W.F. Trager Characteristics of warfarin hydroxylation catalyzed by human liver microsomes Drug Metab Dispos 17 1989 265 270
27. D. Hickman, J. Wang, Y. Wang, J. Unadkat Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities Drug Metab Dispos 26 1998 207 215
28. A.P. Li, M.K. Reith, A. Rasmussen, J.C. Gorski, S.D. Hall, L Xu Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin Chem Biol Interact 107 1997 17 30
29. C.B. Trapnell, C. Jamis-Dow, R.W. Klecker, J.M. Collins Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole Antimicrob Agents Chemother 41 1997 924 926
30. R. Hafner, J. Bethel, M. Power, B. Landry, M. Banach, L Mole Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers Antimicrob Agents Chemother 42 1998 631 639
31. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara Jr, S.D. Hall The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 1998 133 143
32. K.L. Kunze, L.C. Wienkers, K.E. Thummel, W.F. Trager Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies Drug Metab Dispos 24 1996 414 421
33. H.J. Gill, J.L. Maggs, S. Madden, M. Pirmohamed, B.K. Park The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole Br J Clin Pharmacol 42 1996 347 353